| Mr Daniel B Knight, NP | |
|
112 W. Park Ave, Ash Fork, AZ 86320 | |
| (855) 277-5901 | |
| (833) 731-0353 |
| Full Name | Mr Daniel B Knight |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 20 Years |
| Location | 112 W. Park Ave, Ash Fork, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932173127 | NPI | - | NPPES |
| RN103251 | Other | AZ | RN LICENSE |
| AP2115 | Other | AZ | FNP CERTIFICATE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | AP2115 (Arizona) | Primary |
| 363LP2300X | Nurse Practitioner - Primary Care | RN103251 (Arizona) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Yavapai Regional Medical Center | Prescott, AZ | Hospital |
| Entity Name | North Country Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073583472 PECOS PAC ID: 8820981053 Enrollment ID: O20040210001107 |
News Archive
Following the uproar after the release of the controversial Foreign Office memos that suggested that Pope Benedict XVI's visit to UK this September could be marked by the launch of "Benedict" condoms. The Foreign Office document, called "The ideal visit would see...", said the Pope could be invited to open an abortion clinic, launch a range of condoms, singing a charity duet with the Queen and bless a gay marriage. The document raised the issues of child abuse by priests and urged the "sacking" of "dodgy bishops" and opening helplines for abused children.
The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread to over 192 countries and territories, causing an enormous loss of lives and economic devastation.
A draft policy from the FDA's counterfeit drug task force, concerns drugs marketed in the United States that do not have required FDA approval and emphasizes the regulatory actions and the use of new technologies for safeguarding the integrity of the U.S. drug supply.
OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.
› Verified 3 days ago
| Entity Name | Alchemy Apothecary |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154094779 PECOS PAC ID: 3577952209 Enrollment ID: O20211117002905 |
News Archive
Following the uproar after the release of the controversial Foreign Office memos that suggested that Pope Benedict XVI's visit to UK this September could be marked by the launch of "Benedict" condoms. The Foreign Office document, called "The ideal visit would see...", said the Pope could be invited to open an abortion clinic, launch a range of condoms, singing a charity duet with the Queen and bless a gay marriage. The document raised the issues of child abuse by priests and urged the "sacking" of "dodgy bishops" and opening helplines for abused children.
The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread to over 192 countries and territories, causing an enormous loss of lives and economic devastation.
A draft policy from the FDA's counterfeit drug task force, concerns drugs marketed in the United States that do not have required FDA approval and emphasizes the regulatory actions and the use of new technologies for safeguarding the integrity of the U.S. drug supply.
OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Daniel B Knight, NP 419 S 3rd St, Williams, AZ 86046-2448 Ph: (855) 277-5901 | Mr Daniel B Knight, NP 112 W. Park Ave, Ash Fork, AZ 86320 Ph: (855) 277-5901 |
News Archive
Following the uproar after the release of the controversial Foreign Office memos that suggested that Pope Benedict XVI's visit to UK this September could be marked by the launch of "Benedict" condoms. The Foreign Office document, called "The ideal visit would see...", said the Pope could be invited to open an abortion clinic, launch a range of condoms, singing a charity duet with the Queen and bless a gay marriage. The document raised the issues of child abuse by priests and urged the "sacking" of "dodgy bishops" and opening helplines for abused children.
The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread to over 192 countries and territories, causing an enormous loss of lives and economic devastation.
A draft policy from the FDA's counterfeit drug task force, concerns drugs marketed in the United States that do not have required FDA approval and emphasizes the regulatory actions and the use of new technologies for safeguarding the integrity of the U.S. drug supply.
OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.
› Verified 3 days ago